Trial reportArthritis & rheumatology (Hoboken, N.J.)2026
The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Trial report in Arthritis & rheumatology (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anti-neutrophil cytoplasmic antibody-associated vasculitis: biological insights and biomarker-guided disease management.Nature reviews. Nephrology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveEar, nose, and throat (ENT) manifestations are common in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). There is an unmet need for drugs to target these manifestations. Granuloma formation is characteristic of proteinase 3 (PR3)-AAV. In a zebrafish model, niclosamide inhibits PR3-induced granuloma formation. We hypothesized that intranasal niclosamide would reduce AAV-associated ENT symptoms.
methodsPROTECT-V was a randomized, double-blind, placebo-controlled platform trial evaluating pre-exposure prophylaxis agents against COVID-19 infection. This subanalysis includes patients from a single center with AAV, enrolled into the intranasal niclosamide arm. Clinical data were retrospectively collected for nine months before, during, and nine months after treatment. Researchers were blinded to treatment allocation.
resultsOf 32 (14 niclosamide; 18 placebo) patients, 11 (34%) were female; the median age was 69 (interquartile range [IQR] 59-75) years. Median prior AAV disease duration was 5.4 (IQR 1.9-13.1) years; 19 (59%) had active disease in the year before treatment. Median treatment exposure was 200 (IQR 109-251) days. During treatment, ENT symptoms were identified in 1 of 14 (7%) of the niclosamide group compared with 7 of 18 (39%) of the placebo group (P = 0.04). No significant difference between groups was found in the nine months before or after treatment. Among PR3-ANCA-positive patients, 0 of 10 in the niclosamide group compared to 5 of 9 (56%) in the placebo group had ENT symptoms during treatment.
conclusionThese data are a signal of potential clinical effect on ENT manifestations in AAV. They support a role for the IL-6 and STAT3 pathway in AAV; intranasal niclosamide or other drug candidates in this pathway warrant further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.